Sectoral Asset Management Inc. Buys Shares of 47,700 Carlsmed, Inc. $CARL

Sectoral Asset Management Inc. bought a new stake in Carlsmed, Inc. (NASDAQ:CARL) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 47,700 shares of the company’s stock, valued at approximately $589,000. Sectoral Asset Management Inc. owned approximately 0.18% of Carlsmed as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Wesbanco Bank Inc. acquired a new stake in Carlsmed in the fourth quarter valued at approximately $457,000. TD Waterhouse Canada Inc. boosted its stake in Carlsmed by 15.2% in the fourth quarter. TD Waterhouse Canada Inc. now owns 175,405 shares of the company’s stock valued at $2,154,000 after acquiring an additional 23,163 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in Carlsmed in the third quarter valued at approximately $37,000. Woodline Partners LP acquired a new stake in Carlsmed in the third quarter valued at approximately $311,000. Finally, Zimmer Partners LP acquired a new stake in shares of Carlsmed during the third quarter worth $670,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Truist Financial decreased their target price on shares of Carlsmed from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. Wall Street Zen upgraded shares of Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. BTIG Research reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Carlsmed in a report on Wednesday, May 6th. Zacks Research raised shares of Carlsmed from a “strong sell” rating to a “hold” rating in a report on Thursday, March 26th. Finally, The Goldman Sachs Group cut their price objective on shares of Carlsmed from $19.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $19.33.

Carlsmed Price Performance

CARL opened at $12.11 on Monday. Carlsmed, Inc. has a fifty-two week low of $8.50 and a fifty-two week high of $17.19. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.67 and a current ratio of 11.88. The company has a fifty day moving average of $10.28 and a two-hundred day moving average of $11.98. The stock has a market capitalization of $329.21 million and a price-to-earnings ratio of -4.82.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. The company had revenue of $16.12 million during the quarter. Carlsmed had a negative net margin of 57.76% and a negative return on equity of 60.74%. On average, research analysts expect that Carlsmed, Inc. will post -1.35 earnings per share for the current year.

Carlsmed Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).